For Eisai and Biogen's Leqembi, first FDA-approved Alzheimer's blood test will take time to boost launch: analyst
With the FDA approval of the first blood-based test to help diagnose Alzheimer’s disease, Eisai and Biogen’s acceleration plan for Leqembi has been set in motion. But bending the Leqembi sales curve may still take time, a Mizuho analyst argued.
With the FDA approval of the first blood-based test to help diagnose Alzheimer’s disease, Eisai and Biogen’s acceleration plan for Leqembi has been set in motion. But bending the Leqembi sales curve may still take time, a Mizuho analyst argued.
